Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology.
As the former CEO of Santen Inc., the US subsidiary of a 130-year-old Japanese pharmaceutical company, she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization, and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical Development (US, Europe, and Japan) for 7 years and CEO for 8 years. Prior to Santen, she spent 9 years at Alcon, joining as Sr. Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology.
Dr. Graves currently serves as an Independent Director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix. She previously held board positions at Encore Vision (2011 – 2017; acquired by Novartis), Envisia Therapeutics (2014 – 2017; assets acquired by Aerie Pharmaceuticals), TearLab Corporation (2005 – 2018), and Aerpio Therapeutics (2012 – 2017). Dr. Graves also serves as Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund.
She co-founded OWL (Ophthalmic World Leaders) and Glaucoma 360. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Psychobiology/Neuroscience from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris.
In 2015, Glaucoma Research Foundation presented The Catalyst Award to Dr. Graves in recognition of her outstanding leadership and many contributions to ophthalmology and for her dedicated service on the GRF Board of Directors. She currently serves on the Glaucoma Research Foundation Board’s Research Committee and Leadership Committee.
We will mail Gleams anywhere in the United States and Canada, but we do not mail internationally. Please sign up for the email edition if you live outside of the US or Canada.